This technology offers a novel, mechanism-based therapeutic method using oxytocin and specific compounds to treat social-affective deficits in behavioral variant frontotemporal dementia (bvFTD).
Background: Behavioral variant frontotemporal dementia (bvFTD) is a prevalent form of dementia characterized by severe social and emotional impairments, significantly impacting patients’ quality of life. Despite the high incidence of bvFTD, no effective cure or targeted treatment currently exists. Research into the neural mechanisms underlying these deficits revealed potential therapeutic targets within the brain regions responsible for social behavior. This unmet medical need and scientific insight motivated the development of a new treatment approach leveraging neuropeptides and receptor- and channel-modulating compounds.
Technology Overview: This innovative technology employs a mechanism-based method to address the social-affective challenges observed in bvFTD patients. Central to this approach is the nasal administration of the neuropeptide oxytocin, known for its role in social bonding and behavior modulation. In conjunction, two compounds are directly infused into the dorsal medial prefrontal cortex (dmPFC), a brain area critical for regulating social and affective functions. These compounds act on neural receptors and channels to restore disrupted neuron activity. The combination of a non-invasive nasal delivery system for oxytocin and targeted infusion of receptor-modifying compounds distinguishes this method from existing treatments. This strategy harnesses both peripheral and central nervous system deliveries, and encompasses neuromodulator, receptors, and channels, maximizing therapeutic efficacy while minimizing side effects and invasiveness. The technology offers a promising avenue for disease modification in bvFTD by directly targeting the underlying neural mechanisms rather than merely alleviating symptoms. Additionally, this approach has potential applications beyond bvFTD, including treatment of autism and related neuropsychiatric disorders, where social-affective dysfunctions similarly impair patient outcomes.
https://suny.technologypublisher.com/files/sites/adobestock_1859187070.jpeg Picture for reference only, not a depiction of the invention.
Advantages: • Non-invasive administration of oxytocin via nasal delivery enhances patient compliance and reduces treatment burden. • Mechanism-based approach focuses on restoring neural circuitry, offering potential for lasting therapeutic effects rather than symptomatic relief. • Demonstrated efficacy in a validated animal model supports translational potential for human clinical use. • Potentially applicable to other disorders involving social-affective deficits, expanding its clinical impact.
Applications: • Treatment of behavioral variant frontotemporal dementia (bvFTD) to improve social and emotional functioning. • Therapeutic intervention for autism spectrum disorders and other neuropsychiatric conditions with social-affective impairments. • Research tool for investigating neural mechanisms underlying social behavior and neurodegenerative diseases. • Potential development platform for new drugs and approaches targeting neural receptor and ion channel pathways involved in social cognition.
Intellectual Property Summary: Patent application 63/935,562 filed on 12/10/2025
Stage of Development: 3 The technology is at an early preclinical stage, reflecting proof of concept for the dual modality (intranasal oxytocin + intra-dmPFC infusion) approach, with anticipated validation in relevant in vivo models.
Licensing Status: This technology is available for licensing.